Vertex Pharmaceuticals Incorporated $VRTX Stock Bought by Vise Technologies Inc.

Vise Technologies Inc. raised its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.5% during the 3rd quarter, Holdings Channel reports. The firm owned 9,344 shares of the pharmaceutical company’s stock after buying an additional 1,462 shares during the quarter. Vise Technologies Inc.’s holdings in Vertex Pharmaceuticals were worth $4,885,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of VRTX. Bangor Savings Bank increased its holdings in Vertex Pharmaceuticals by 0.4% in the 2nd quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock worth $2,220,000 after buying an additional 20 shares during the period. Trust Point Inc. lifted its stake in Vertex Pharmaceuticals by 2.7% during the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after acquiring an additional 21 shares during the period. Integrated Advisors Network LLC lifted its stake in Vertex Pharmaceuticals by 1.4% during the 3rd quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock valued at $850,000 after acquiring an additional 22 shares during the period. Glenview Trust Co lifted its stake in Vertex Pharmaceuticals by 0.3% during the 3rd quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company’s stock valued at $3,541,000 after acquiring an additional 22 shares during the period. Finally, Cannell & Spears LLC boosted its holdings in shares of Vertex Pharmaceuticals by 1.2% in the 1st quarter. Cannell & Spears LLC now owns 1,983 shares of the pharmaceutical company’s stock valued at $885,000 after acquiring an additional 23 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

VRTX has been the topic of a number of research reports. Truist Financial increased their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. TD Cowen boosted their target price on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $550.00 to $650.00 and gave the company an “overweight” rating in a report on Tuesday. Weiss Ratings raised Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, October 16th. Finally, Rothschild & Co Redburn lifted their price objective on Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $596.11.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $530.76 on Wednesday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $403.16 and a fifty-two week high of $568.67. The company has a fifty day moving average of $522.98 and a two-hundred day moving average of $480.37. The stock has a market capitalization of $134.71 billion, a price-to-earnings ratio of 34.15, a PEG ratio of 2.65 and a beta of 0.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 22.40% and a net margin of 30.70%. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the company posted $4.80 EPS. The company’s revenue was up 11.8% on a year-over-year basis. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.74 earnings per share for the current year.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, topping estimates, supported by Vertex’s cystic-fibrosis franchise and growth from newer medicines including CASGEVY and JOURNAVX. The company also raised its 2026 sales outlook. Read More.
• Positive Sentiment: Management expressed confidence in the anticipated launch of povetacicept for IgA nephropathy ahead of an FDA decision, an important potential growth driver beyond cystic fibrosis. Several analysts also raised their price targets after the results. Read More. · Read More.
• Negative Sentiment: Adjusted earnings of $4.76 per share fell short of estimates. Acquisition and launch-related spending weighed on profit, while sales of the newer pain drug JOURNAVX were described as light—dampening the market’s reaction to the revenue beat. Read More.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.